TNFRSF17 and Miyoshi myopathy: In relapsed/refractory (RR) MM [2], excellent responses have been reported to B-cell maturation antigen (BCMA)-targeting immunotherapy, and specifically to anti-BCMA chimeric antigen receptor T-cell (CART) therapy [9,12,13,14,15].